If you have looked into peptide therapy in Michigan lately, you have probably seen confident claims in both directions. Federal policy moved three times in 2026, and each step was narrower than the headlines suggested. Here is where things stand as of November 2, 2026.
What is peptide therapy, and which peptides are FDA approved?
Peptides are short chains of amino acids, and the word covers very different products. Three groups make the rules easier to follow.
- FDA-approved peptide drugs. Semaglutide (Wegovy), tirzepatide (Zepbound) and tesamorelin (Egrifta) were reviewed by the FDA for specific uses. Tesamorelin's label covers excess abdominal fat in adults with HIV-related lipodystrophy.
- Compounded peptides. A pharmacy prepares these for an individual prescription. The FDA notes that compounded drugs are not FDA approved and that it does not review their safety, effectiveness or quality before they reach the market.
- Research use only products. These are sold online with labels like "for research purposes" or "not for human consumption." The FDA has warned sellers of these products and describes them as being of unknown quality.
What changed for BPC-157 and other peptides in 2026?
- April: The FDA took 12 peptides, including BPC-157, off Category 2, its list of substances that may pose significant safety risks, after the nominations to add them to the compounding list were withdrawn. Removal alone did not authorize compounding.
- July 23 to 24: The Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 for the list. It backed six of the seven peptides it reviewed. FDA staff had opposed those recommendations, and the committee's vote is not binding.
- October 28: HHS issued an interim enforcement discretion policy covering BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon, with public comments due November 13. Its conditions include an FDA-registered ingredient source, a certificate of analysis and adverse event reporting.
What didn't change?
None of these six peptides is FDA approved, and none has been added to the 503A list. HHS says plainly that its policy does not grant FDA approval or establish clinical safety and effectiveness. Adding a peptide to the list takes formal FDA rulemaking, which legal analysts say can run from many months to years. HHS has also said it may revisit the policy if a safety signal or product quality problem appears. A second advisory meeting on other peptides is planned before the end of February 2027.
Is BPC-157 legal in Michigan?
Federally, a compounded version now has a conditional path through a licensed pharmacy or physician, but enforcement discretion is a decision not to act, and it is different from approval or a change in the law. States can take their own view. An industry leader told Reuters that some states may not follow the federal move, and as of early November we have not seen a Michigan-specific announcement. Michigan's licensing agency, LARA, says pharmacies doing business here need a Michigan license wherever they are located, and you can check one with its Verify a License tool.
What does the research say about BPC-157?
BPC-157 is often discussed for tendon and joint recovery, though the FDA committee evaluated it for ulcerative colitis. A 2025 systematic review in HSS Journal found 36 orthopaedic studies, 35 of them preclinical and one clinical, and concluded that clinical safety in humans remains unknown. If you compete in a tested sport, note that the U.S. Anti-Doping Agency lists BPC-157 as prohibited.
What does a responsible clinic do?
Good care tends to look similar for any medication:
- A licensed prescriber reviews your history and goals before prescribing.
- Baseline labs are ordered when they are relevant, then repeated on a set schedule.
- The prescription goes to a licensed pharmacy that can document where the ingredient came from.
- An approved option is discussed first if one exists for your condition.
- You get follow-up visits, a way to report side effects, and a set point to decide whether to continue.
What questions should you ask any clinic?
- Is this medication FDA approved, or is it compounded?
- Who is prescribing it, and will that person review my labs and history?
- Which pharmacy prepares it, and is it licensed in Michigan?
- Can I see the certificate of analysis for the ingredient?
- What is the evidence for my goal?
- How will we measure progress, and when would we stop?
- Who do I call about a reaction?
Where does Total Health Systems fit?
Whatever you and your prescriber decide, we can help with the bigger picture. Primary care and functional medicine lab testing can give you a clearer starting point. An InBody scan shows how your muscle and fat change over time, and nutrition counseling or our 12-week First Line Therapy program can support your habits. For a nagging tendon or joint, our goal with chiropractic care and physical therapy is to find out what is driving it and help you move comfortably.
This article is general education and is not medical advice. Peptide rules are changing quickly, so talk with your prescriber and confirm current FDA and Michigan requirements before starting any peptide.